Hetal Dholaria
A5044706959- Glioma Diagnosis and Treatment
- Neuroblastoma Research and Treatments
- Radiomics and Machine Learning in Medical Imaging
- Meningioma and schwannoma management
- Childhood Cancer Survivors' Quality of Life
- Neurofibromatosis and Schwannoma Cases
- Sarcoma Diagnosis and Treatment
- Testicular diseases and treatments
- Immunotherapy and Immune Responses
- Cancer Immunotherapy and Biomarkers
- Cancer Diagnosis and Treatment
- MRI in cancer diagnosis
- Immune Cell Function and Interaction
- Brain Metastases and Treatment
- Acute Lymphoblastic Leukemia research
- Fetal and Pediatric Neurological Disorders
- Genetic Syndromes and Imprinting
- Lymphoma Diagnosis and Treatment
- Immune cells in cancer
- Genomics and Rare Diseases
- DNA Repair Mechanisms
- Viral Infections and Outbreaks Research
- Cancer Treatment and Pharmacology
- Medical Imaging and Pathology Studies
- Renal cell carcinoma treatment
Perth Children's Hospital
2020-2025
Princess Margaret Hospital for Children
2018-2025
The University of Western Australia
2018-2025
The Kids Research Institute Australia
2016-2025
University of Colorado Denver
2018
Children's Hospital Colorado
2018
Princess Máxima Center
2018
Lucile Packard Children's Hospital
2017
Lurie Children's Hospital
2017
Cincinnati Children's Hospital Medical Center
2017
Purpose Diffuse intrinsic pontine glioma (DIPG) is a brainstem malignancy with median survival of < 1 year. The International and European Society for Pediatric Oncology DIPG Registries collaborated to compare clinical, radiologic, histomolecular characteristics between short-term survivors (STSs) long-term (LTSs). Materials Methods Data abstracted from registry databases included patients North America, Australia, Germany, Austria, Switzerland, the Netherlands, Italy, France, United...
Abtract Background This study describes imaging features of diffuse intrinsic pontine glioma (DIPG) and correlates with overall survival (OS) histone mutation status in the International DIPG Registry (IDIPGR). Methods Four hundred cases submitted to IDIPGR a local diagnosis baseline MRI were evaluated by consensus review 2 neuroradiologists; 43 excluded (inadequate or alternative diagnoses). Agreement between reviewers, association status, univariable multivariable analyses relative OS...
<div>AbstractPurpose:<p>Tropomyosin receptor kinase (TRK) fusions are detected in less than 2% of central nervous system tumors. There limited data on the clinical course affected patients.</p>Experimental Design:<p>We conducted an international retrospective cohort study patients with TRK fusion–driven tumors.</p>Results:<p>A total 119 were identified. The median age at time diagnosis was 4.5 years. majority reported to have a histology consistent...
<p>Supplementary Figure S1. Diagram of population patients.</p>
<p>Supplementary Figure S2. A) Hazard ratio for progression or death according to clinical characteristics. B) LGG: Low-grade glioma, HGG: High-grade glioma</p>
<p>Supplementary Data S1. Definition of response, Description response criteria used by sites to evaluate tumor extend resection, resection sites.</p>
Diffuse intrinsic pontine gliomas (DIPG) generally occur in young school-age children, although can adolescents and adults. The purpose of this study was to describe clinical, radiological, pathologic, molecular characteristics patients ≥10 years age with DIPG enrolled the International Registry (IDIPGR).Patients at diagnosis IDIPGR imaging confirmed were included. primary outcome overall survival (OS) categorized as long-term survivors (LTS) (≥24 months) or short-term (STS) (<24...
Diffuse intrinsic pontine glioma (DIPG) remains a clinico-radiologic diagnosis without routine tissue acquisition. Reliable imaging distinction between DIPG and other tumors with potentially more favorable prognoses treatment considerations is essential.Cases submitted to the International registry (IDIPGR) histopathologic and/or radiologic data were analyzed. Central review was performed on diagnostic brain MRIs (if available) by two neuro-radiologists. Imaging features suggestive of...
Abstract Background Molecular profiling of the tumour immune microenvironment (TIME) has enabled rational choice immunotherapies in some adult cancers. In contrast, TIME paediatric cancers is relatively unexplored. We speculated that a more refined appreciation childhood cancers, rather than reliance on commonly used biomarkers such as mutation burden (TMB), neoantigen load and PD-L1 expression, an essential prerequisite for improved solid Methods combined immunohistochemistry (IHC) with RNA...
Abstract Purpose: TRK fusions are detected in less than 2% of central nervous system tumors. There limited data on the clinical course affected patients. Experimental design: We conducted an international retrospective cohort study patients with fusion-driven CNS Results: 119 were identified. The median age at time diagnosis was 4.5 years. majority reported to have a histology consistent high-grade glioma (HGG) (57.1%) followed by low-grade (LGG) (27.7%). Pediatric had better prognosis...
Introduction Ependymomas (EPN) are the third most common malignant brain cancer in children. Treatment strategies for pediatric EPN have remained unchanged over recent decades, with 10-year survival rates stagnating at just 67% children aged 0-14 years. Moreover, a proportion of patients who survive treatment often suffer long-term neurological side effects as result therapy. It is evident that there need safer, more effective treatments patients. There ten distinct subgroups EPN, each their...
Abstract BACKGROUND Primary intracranial germ cell tumors (GCTs) are rare heterogeneous tumors; germinoma accounts for two-thirds of cases. While neoadjuvant chemotherapy followed by response-based reduced radiotherapy dose and field is the established approach managing localized CNS germinomas, controversy persists regarding treatment primary metastatic disease. Additionally, limited research exists on utilization in germinoma. METHODS A retrospective multi-institutional analysis was...
Abstract BACKGROUND Despite treatment intensification, survival for high-risk subgroups of medulloblastoma (MB) such as MYC-amplified Group 3 (Gr3-II) and p53-mutant SHH (SHH-3p53mut) have remained dismal with overall around 40% 20% respectively. Our previous studies shown that the DNA-damage response inhibitors (DDRis) prexasertib ceralasertib enhance effects CSI using cell line-derived orthotopic mouse models. However, patient-derived xenografts (PDOXs) are considered superior models...
Abstract Germline predisposition has a significant role in paediatric cancer. However, the optimal approach to identifying cancer-causing germline pathogenic variants (GPV) children, and even prevalence of GPV among children with cancer, remain unclear. Here we report our findings from comprehensive survey 496 poor-prognosis By integrating tumour molecular profiling identified 15.5% patients, 48.1% whom had not met clinical genetic testing criteria. Although cancer type was outside...